Skip to main content

Table 3 Effects of zafirlukast in subjects maintained on ics

From: Tolerance and rebound with zafirlukast in patients with persistent asthma

 

ICS-treated + Placebo Change from baseline

ICS-treated + Zafirlukast Change from baseline

 

Baseline (N = 8)

Weeks 0–5 (N = 8)

Weeks 6–10 (N = 8)

Week 11–12 (N = 8)

*W/D (N = 8)

Baseline (N = 15)

Weeks 0–5 (N = 15)

Weeks 6–10 (N = 13)

Week 11–12 (N = 13)

*W/D (N = 11)

PEFR a.m., L/min

353 (± 32.3)

+13.9 (± 6.1)

+21.1 (± 9.6)

+17.5 (± 12.2)

+10.4 (± 6.6)

389 (± 21.2)

+15.7 (± 5.0)

+16.7 (± 6.1)

+2.7 (± 15.2)

-7.4 (± 6.3)

PEFR p.m., L/min

373 (± 32.8)

+9.4 (± 10.0)

+6.4 (± 15.0)

+17.7 (± 12.1)

+5.3 (± 6.2)

404 (± 20.0)

+10.5 (± 4.9)

+10.9 (± 5.8)

-0.6 (± 15.0)

-23.1 (± 6.6)

FEV1, mL

2,567 (± 225)

-134 (± 67.7)

-130 (± 47.2)

-23.8 (± 93.6)

+78.8 (± 59.6)

2,540 (± 179)

+105 (± 72.5)

-39.2 (± 74.7)

+144 (± 106)

-94.5 (± 48.0)

β2-agonist use per day

3.9 (± 0.6)

-0.8 (± 0.47)

-1.2 (± 0.68)

-0.3 (± 1.0)

-0.4 (± 0.4)

3.7 (± 0.5)

-0.8 (± 0.25)

-0.9 (± 0.32)

-1.1 (± 0.4)

+0.6 (± 0.47)

Severity score

2.0 (± 0.02)

-0.3 (± 0.1)

-0.3 (± 0.1)

-0.03 (± 0.04)

-0.1 (± 0.1)

1.8 (± 0.7)

-0.3 (± 0.1)

-0.3 (± 0.1)

-0.4 (± 0.2)

+0.1 (± 0.2)

**Total mornings

5.7 (± 0.8)

-1.8 (± 0.8)

-3.2 (± 0.9)

-2.3 (± 1.4)

-0.8 (± 2.2)

3.2 (± 0.6)

-0.7 (± 0.4)

-1.1 (± 0.7)

-0.6 (± 0.5)

+0.4 (± 0.3)

**Total awakenings

1.5 (± 0.9)

-0.8 (± 0.7)

-0.8 (± 0.5)

-1.1 (± 0.7)

+0.4 (± 1.1)

1.8 (± 0.7)

-0.6 (± 0.5)

-0.9 (± 0.6)

-1.6 (± 0.7)

+1.4 (± 1.0)